FDA approval of KwikPen aims to simplify obesity treatment and improve patient choice
Indianapolis, 26 February 2026 – Eli Lilly and Company has received approval from the U.S. Food and Drug Administration to expand the label of Zepbound, its injectable obesity treatment, to include a four-dose single-patient KwikPen. The new device delivers a full month of treatment in one pen, offering patients a simpler and more flexible way to manage long-term weight loss therapy.
In simple terms, the newly approved KwikPen allows people prescribed Zepbound to take one weekly injection using a single device instead of multiple single-dose options. This is designed to make treatment more convenient while giving patients and doctors more choice based on lifestyle, comfort, and access needs.
Zepbound is currently the most prescribed injectable medication for obesity management in the United States. Clinical studies have shown that adults using the medicine, along with diet and exercise, achieved significant and sustained weight loss. In advanced trials, some patients lost an average of up to 50 pounds over a 72-week period, highlighting the drug’s strong effectiveness compared to earlier treatment options.
Through LillyDirect, the company’s digital health platform, eligible self-pay patients with a valid prescription can access Zepbound in either the KwikPen or single-dose vials. Pricing for the starting 2.5 mg dose begins at $299 per month, positioning the treatment at a lower cost compared with many other branded GLP-1 obesity medicines.
Lilly says the move reflects growing demand for accessible weight management solutions. More than one million patients used LillyDirect services in 2025, and a significant share of new patients starting branded weight management therapies chose Zepbound through the self-pay model.
Zepbound works by targeting hormones involved in appetite and food intake, helping people feel fuller and eat less. It is approved for adults with obesity, as well as some adults who are overweight with related medical conditions. It is also approved to help improve moderate-to-severe obstructive sleep apnea in adults with obesity. As with all prescription medicines, doctors emphasize that results vary and that treatment should be combined with healthy eating and physical activity.
The new KwikPen approval marks another step in Lilly’s broader strategy to expand treatment options for chronic conditions such as obesity, while focusing on ease of use and patient support.
